News & Media

Recent updates from Arcutis.

August 2, 2021

Arcutis Announces Additions to its Investor Relations and Communications Team

July 21, 2021

Arcutis Advances Science of Psoriasis Drug Development with New Precision Method for Measuring Mild-to-Moderate Psoriasis

July 12, 2021

Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis

July 8, 2021

Arcutis Joins with Habitat for Humanity of Ventura County to Construct and Decorate Playhouses for Military and Veteran Families

July 1, 2021

Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo

June 23, 2021

Greg Sukay Joins Arcutis as Vice President of Manufacturing and Process Technologies

June 9, 2021

Arcutis Announces Appointment of Sue-Jean Lin to Board of Directors

June 1, 2021

Rajvir Madan Joins Arcutis as Chief Digital and Information Officer

May 6, 2021

Arcutis Biotherapeutics Showcases Pivotal DERMIS-1 and -2 Phase 3 Trial Data for Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis at EADV Spring Symposium 2021

May 4, 2021

Arcutis Announces First Quarter 2021 Financial Results and Provides Business Update

May 3, 2021

Arcutis to Present New Roflumilast Cream Phase 3 Data at The European Academy of Dermatology and Venereology (EADV) Spring Symposium

April 28, 2021

Arcutis to Present at the 2021 Truist Securities Life Sciences Summit

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download